You are here: Industry Insights > Japan

News List

Blincyto Approved In Japan americanpharmaceuticalreview
September 27, 2018
Amgen announced the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Blincyto (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Blincyto was developed in Japan by Amgen
Chugai, Nippon Shinyaku bring Gazyva in Japan biospectrumasia
September 03, 2018
Chugai obtained a manufacturing and marketing approval in early July.
Astellas announces approval of Linzess Tablets in Japan biospectrumasia
August 29, 2018
Linzess Tablets 0.25 mg were licensed from Ironwood Pharmaceuticals and have been developed and commercialized in Japan by Astellas
AstraZeneca gets further approval for Tagrisso in Japan pharmaphorum
August 22, 2018
AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cancer (NSCLC), further expanding its currently authorised use in this
Linzess Approved in Japan for Additional Indication americanpharmaceuticalreview
August 22, 2018
Astellas Pharma and Ironwood Pharmaceuticals announced approval has been obtained in Japan for the guanylate cyclase-C receptor agonist Linzess Tablets 0.25 mg (linaclotide) for the additional indication of chronic constipation.
Medtronic introduces IN.PACT Admiral DCB in Japan biospectrumasia
August 20, 2018
IN.PACT Admiral DCB is a clinically proven, primary endovascular therapy that treats femoropopliteal disease, reduces interventions, and preserves future treatment options.
Pharma reps get more respect from doctors in Japan. What's the takeaway for U.S. reps? fiercepharma
August 07, 2018
Looking for a place where pharma sales reps are respected and influential? Try Japan.
Japan's Otsuka Pharma to acquire Visterra for $430 mn biospectrumasia
July 19, 2018
Visterra's pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases.
Lynparza Approved in Japan for BRCA-Mutated Metastatic Breast Cancer americanpharmaceuticalreview
July 11, 2018
AstraZeneca and Merck announced Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2) neg
Takeda bags Japan's approval for ulcerative colitis drug biospectrumasia
July 09, 2018
Entyvio was approved in the European Union and the U.S. in May 2014 for the treatment of adults with moderately to severely active UC

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page